Gene-Environment Neuropsychiatry (GENe)
|Dr Chad Bousmanemail@example.com||+61 3 9035 6667||View page|
Our objective is to advance personalised psychiatry via discovery, development and evaluation of gene by environment interactions relevant to psychiatry practice.
Our studies are based on a framework that suggests both genetic and environmental factors contribute to psychiatric disorders. We primarily focus on psychotic (e.g. schizophrenia) and mood (e.g. depression) disorders with an emphasis on:
- Discovery of distinct variation and environmental interaction with genotypic, transcriptomic, and/or proteomic networks/pathways associated with illness onset, course, and treatment response.
- Development of ‘omic’-based clinical decision-making tools for use in screening, diagnosis, staging, prognosis, and/or treatment of mental illness.
- Evaluation of the efficacy/utility of ‘omic’-based decision-making tools in clinical practice.
Dorothea Lesche, Post-Docotral Fellow
Shaki Mostaid, PhD Student
Chenxing Liu, PhD Student
Ye Tian, PhD Student
Suriati Saini, PhD Student
Sandra Luza Cornejo, Research Fellow
Avril Pereira, Research Fellow
Prof Stan Skafidas (Centre for Neural Engineering, University of Melbourne)
Prof Jane Gunn (Primary Care Research Unit, University of Melbourne)
Prof Ashley Bush (Florey Institute of Neuroscience and Mental Health, Melbourne)
Prof Con Stough (Centre for Human Psychopharmacology, Swinburne University of Technology)
Prof Chee Ng (The Melbourne Clinic)
Prof Malcolm Hopwood (Albert Road Clinic, Melbourne)
Prof Cynthia Weickert, Neuroscience Research Australia
A/Prof Daniel Mueller (Pharmacogenetics Research Clinic, Centre for Addiction and Mental Health, University of Toronto, Canada)
A/Prof Stephen Glatt (Psychiatric Genetic Epidemiology & Neurobiology Laboratory, SUNY Upstate Medical University, Syracuse, New York)
A/Prof Boadie Dunlop, (Mood and Anxiety Disorders Program, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia)
Prof Tianmei Si (Department of Clinical Pharmacology, Institute of Mental Health, Peking University, Beijing, China)
Prof Jun Soo Kwon (Institute of Human Behavioral Medicine, Seoul National University College of Medicine, South Korea)
Liu, C, Bousman CA, Pantelis, C, Skafidas E, Zhang D, Yue W, Everall IP. (2017). Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. Translational Psychiatry, 7(2), e1037.
Bousman CA, Gunn JM, Potiriadis M, Everall IP. (2017). Polygenic phenotypic plasticity moderates the effects of severe childhood abuse on depressive symptom severity in adulthood: A 5-year prospective cohort study. The World Journal of Biological Psychiatry, 18(1): 75-81.
Mostaid MS, Mancuso, S, Liu, CS, Sundram S, Pantelis C, Everall IP, Bousman CA. (2017). Meta-analysis reveals associations between genetic variation in the 5’ and 3’ regions of neuregulin-1 and schizophrenia. Translational Psychiatry, 7, e1004.
Bousman CA and Hopwood M. (2016). Commercial pharmacogenetic-based decision support tools in psychiatry. The Lancet Psychiatry, 3(6): 585-90.
Bousman, C.A., Yung, A.R., Pantelis, C.P., Ellis, J.A., Chavez, R., Nelson, B., Lin, A., Wood, S.J., Velakoulis, D., McGorry, P.D., Everall, I.P., Foley, D.L. (2013). Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis. Translational Psychiatry, 3(4), e251.
Singh, A.B., Bousman, C.A., Ng, C.H., Byron, K., Berk, M. (2012). ABCB1 Polymorphism Predicts Escitalopram Dose Needed for Remission in Major Depression. Translational Psychiatry, 2(11), e198.